Kristi Nord, MD
Neurology · Louisville, KYNPI 1790931301
Payments from drug & device makers
Across 439 payments — averaging $494.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$142K
- EMD Serono, Inc.$70K
- AbbVie$2K
- Medtronic$1K
- MDD US Operations, LLC$242
- Sanofi$220
- plus $3K from 45 others
What the payments were for
- Consulting fees$14,9937%
- Speaking & faculty fees$166,11976%
- Travel & lodging$29,32813%
- Food & beverage$6,5183%
- Education$2880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$217,247 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 54 | $889,423 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $453,753 |
| Kesimpta PenOfatumumab | 18 | $162,108 |
| RytaryCarbidopa/Levodopa | 22 | $24,878 |
| NourianzIstradefylline | 12 | $22,530 |
| Droxidopa | 11 | $20,613 |
| AptiomEslicarbazepine Acetate | 15 | $17,558 |
| Dalfampridine ErDalfampridine | 35 | $16,599 |
| Ajovy SyringeFremanezumab-Vfrm | 15 | $10,709 |
| Emgality PenGalcanezumab-Gnlm | 12 | $10,557 |
| BriviactBrivaracetam | 11 | $7,993 |
| Lamotrigine ErLamotrigine | 22 | $6,155 |
| Memantine Hcl | 37 | $4,456 |
| Pregabalin | 114 | $3,227 |
| Rivastigmine | 16 | $2,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $44 | $453,75326 claims |
| Amneal Pharmaceuticals LLCRytary | $111 | $24,87822 claims |
| Kyowa Kirin, Inc.Nourianz | $29 | $22,53012 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $43 | $17,55815 claims |
| UCB, Inc.Briviact | $113 | $7,99311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.
Other neurology in Louisville
- Irene LitvanLouisville$2.7M
- Jenny FengLouisville$2M
- Geeta GaneshLouisville$765K
- Peter HederaLouisville$422K
- Gregory CooperLouisville$291K
- Brian PlatoLouisville$267K
- Michael SweeneyLouisville$201K
- Angela HardwickLouisville$187K
- Jeffrey FrankLouisville$181K
- Kaylyn SinicropeLouisville$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.